CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
If you are an adult diagnosed with cancer within the last 10 years find out how you can participate.
Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)
Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.
Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition. This funding will support the Canadian contribution to the DYNAMIC-III international trial, led by the Australasian Gastrointestinal Trials Group (AGITG). Researchers are examining whether circulating tumour DNA (ctDNA) can be used to better select chemotherapy and improve the outcomes of patients after surgical removal of their colorectal cancer.
“This clinical trial will evaluate a new blood test to better predict which patients require additional treatments to increase their chance of cure and which patients do not, allowing us to avoid toxic treatments in patients who have a very low risk of recurrence,” says Canadian co-Chair Dr. Jonathan Loree, BC Cancer Medical Oncologist and Assistant Professor at the University of British Columbia.
Colorectal cancer (CRC) is the second most common cause of cancer death in Canada and one-third of patients diagnosed will have cancer that spreads to their lymph nodes. While surgery is often used to treat these patients, half will have the cancer return.
If surgery was not successful in removing all of the cancer, fragments of cancer DNA (ctDNA) can enter the blood stream. Detecting ctDNA after surgery may identify patients most likely to have cancer come back and help determine who should get extra chemotherapy after surgery.
The practice changing CCTG SC24 randomized phase II/III trial is the first to show that stereotactic body radiation therapy (SBRT) is superior to conventional radiation treatments in alleviating pain from spinal metastases. Findings from the International trial have been published in Lancet Oncology.
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
Eur J Haematol n/a, 2021Monteith BE;Venner CP;Cheung MC;Pater J;Shepherd L;Richardson H;Reece D;Gul E;Lalancette M;Castonguay V;Kukreti V;Tiedemann R;Phua C;Bhella S;Dudebout J;Sherry M;Yen H;Chen BE;Hay AE;
npj Breast Cancer 7: 74, 2021Goodwin PJ;Dowling RJO;Ennis M;Chen BE;Parulekar WR;Shepherd LE;Burnell MJ;Vander Meer R;Molckovsky A;Gurjal A;Gelmon KA;Ligibel JA;Hershman DL;Mayer IA;Whelan TJ;Hobday TJ;Rastogi P;Rabaglio-Poretti M;Lemieux J;Thompson AM;Rea DW;Stambolic V;
J Clin Oncol 39, 2021Ahluwalia M;Parmar A;Chen EX;Jonker DJ;Loree JM;O'Callaghan CJ;Mittman N;Cheung MC;Feilotter H;Monzon JG;Ng DM;Elfiki TA;Hammad N;Lemay F;Tremblay A;Hubay S;Lenehan JG;Salim M;Tu D;Chan KK;
J Clin Oncol 39, 2021Allaf ME;Kim SE;Master VA;McDermott DF;Signoretti S;Cella D;Gupta RT;Cole S;Shuch BM;Lara PLN;Kapoor A;Chin Heng DY;Leibovich BC;Michaelson MD;Choueiri TK;Jewett MAS;Maskens D;Harshman LC;Carducci MA;Haas NB;
J Clin Oncol 39, 2021Renouf DJ;Loree JM;Knox JJ;Kavan P;Jonker DJ;Welch S;Couture F;Lemay F;Tehfe M;Harb M;Aucoin N;Ko Y;Tang PA;Topham JT;Jia S;Du P;Schaeffer DF;Gill S;Tu D;O'Callaghan CJ;
J Clin Oncol 39, 2021Morris VK;Yothers G;Kopetz S;Jacobs SA;Lucas PC;Iqbal A;Boland PM;Deming DA;Scott AJ;Lim HJ;Wolmark N;George TJ;
Cancer Treatment and Research Communications 28: 100421, 2021Nassabein R;Gaudreau PO;Belkaid W;Florescu M;Blais N;
